Paul W. Shabram
Direttore Tecnico/Scientifico/R&S presso BIORA THERAPEUTICS, INC.
Posizioni attive di Paul W. Shabram
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| BIORA THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 25/04/2022 | - |
Storia della carriera di Paul W. Shabram
Precedenti posizioni note di Paul W. Shabram
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Direttore Tecnico/Scientifico/R&S | - | - |
| Ventana Biosciences, Inc. | Fondatore | - | - |
Emergent Travel Health, Inc.
 Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/07/2007 | - |
Formazione di Paul W. Shabram
| University of California, Santa Cruz | Undergraduate Degree |
| University of Phoenix | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 7 |
Posizioni
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Settori
| Consumer Services | 3 |
| Technology Services | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| BIORA THERAPEUTICS, INC. | Health Services |
| Aziende private | 2 |
|---|---|
Emergent Travel Health, Inc.
Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technology Services |
| Ventana Biosciences, Inc. |
- Borsa valori
- Insiders
- Paul W. Shabram
- Esperienza
